NASDAQ:ARWR
$36.05
(
3.98%
)
Friday, 2nd Jun 2023
Arrowhead Research Corporation Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $32.30 | $42.48 | Friday, 2nd Jun 2023 ARWR stock ended at $36.05. This is 3.98% more than the trading day before Thursday, 1st Jun 2023. During the day the stock fluctuated 4.37% from a day low at $34.56 to a day high of $36.07. |
| 90 days | $23.09 | $42.48 | |
| 52 weeks | $23.09 | $48.48 |
Historical Arrowhead Research Corporation prices
| Date | Open | High | Low | Close | Volume |
| 2023-06-02 | $35.49 | $36.07 | $34.56 | $36.05 | 942 367 |
| 2023-06-01 | $34.55 | $35.20 | $33.25 | $34.67 | 1 021 148 |
| 2023-05-31 | $32.98 | $34.91 | $32.91 | $34.41 | 1 793 500 |
| 2023-05-30 | $33.50 | $34.38 | $32.30 | $32.78 | 711 894 |
| 2023-05-26 | $33.50 | $33.89 | $32.97 | $33.60 | 781 754 |
| 2023-05-25 | $35.51 | $35.51 | $33.15 | $33.57 | 989 856 |
| 2023-05-24 | $35.96 | $36.06 | $35.21 | $35.57 | 868 913 |
| 2023-05-23 | $36.65 | $38.55 | $36.27 | $36.28 | 880 425 |
| 2023-05-22 | $36.37 | $37.10 | $36.31 | $36.52 | 613 280 |
| 2023-05-19 | $36.95 | $37.18 | $36.18 | $36.27 | 636 417 |
| 2023-05-18 | $36.97 | $36.97 | $35.49 | $36.28 | 908 042 |
| 2023-05-17 | $37.82 | $37.82 | $36.71 | $37.10 | 929 626 |
| 2023-05-16 | $39.36 | $39.36 | $37.41 | $37.64 | 973 055 |
| 2023-05-15 | $39.37 | $40.89 | $39.02 | $39.89 | 905 903 |
| 2023-05-12 | $39.05 | $39.44 | $38.05 | $39.32 | 981 754 |
| 2023-05-11 | $40.45 | $40.54 | $39.50 | $40.08 | 639 575 |
| 2023-05-10 | $41.28 | $41.28 | $39.46 | $40.49 | 694 167 |
| 2023-05-09 | $39.97 | $41.00 | $39.23 | $40.47 | 638 895 |
| 2023-05-08 | $41.33 | $41.36 | $39.57 | $40.45 | 770 162 |
| 2023-05-05 | $40.70 | $42.48 | $40.48 | $41.38 | 1 311 181 |
| 2023-05-04 | $40.22 | $40.46 | $38.45 | $40.05 | 1 502 634 |
| 2023-05-03 | $37.49 | $40.70 | $36.93 | $40.20 | 2 513 341 |
| 2023-05-02 | $35.46 | $35.99 | $34.58 | $35.38 | 1 157 767 |
| 2023-05-01 | $35.00 | $35.89 | $34.49 | $35.72 | 817 530 |
| 2023-04-28 | $34.79 | $36.02 | $33.66 | $35.41 | 1 005 532 |
| 2023-04-27 | $36.00 | $36.02 | $34.91 | $34.96 | 1 090 868 |
| 2023-04-26 | $34.47 | $35.78 | $33.11 | $35.52 | 1 587 014 |
| 2023-04-25 | $35.02 | $36.00 | $33.44 | $33.58 | 3 609 240 |
| 2023-04-24 | $30.70 | $31.19 | $29.84 | $30.02 | 618 812 |
| 2023-04-21 | $30.17 | $30.90 | $30.05 | $30.87 | 708 036 |
| 2023-04-20 | $30.00 | $30.35 | $29.66 | $29.92 | 654 899 |
| 2023-04-19 | $30.38 | $30.88 | $30.20 | $30.46 | 532 011 |
| 2023-04-18 | $31.64 | $31.64 | $30.10 | $30.40 | 680 109 |
| 2023-04-17 | $30.87 | $31.85 | $30.65 | $31.34 | 1 051 631 |
| 2023-04-14 | $30.47 | $31.42 | $29.97 | $30.46 | 966 092 |
| 2023-04-13 | $28.78 | $31.41 | $28.78 | $30.50 | 1 385 883 |
| 2023-04-12 | $27.81 | $29.74 | $27.43 | $28.56 | 2 182 510 |
| 2023-04-11 | $25.69 | $26.37 | $25.69 | $26.23 | 720 007 |
| 2023-04-10 | $26.00 | $26.00 | $25.23 | $25.51 | 671 204 |
| 2023-04-06 | $25.33 | $26.48 | $24.92 | $26.17 | 758 223 |
| 2023-04-05 | $25.09 | $25.54 | $24.77 | $25.27 | 720 953 |
| 2023-04-04 | $25.73 | $25.75 | $24.64 | $25.16 | 826 291 |
| 2023-04-03 | $25.38 | $25.86 | $25.12 | $25.56 | 856 584 |
| 2023-03-31 | $24.59 | $25.56 | $24.43 | $25.40 | 1 092 347 |
| 2023-03-30 | $24.88 | $24.94 | $24.05 | $24.43 | 697 205 |
| 2023-03-29 | $24.52 | $24.78 | $24.14 | $24.74 | 754 395 |
| 2023-03-28 | $24.25 | $24.59 | $24.12 | $24.26 | 697 881 |
| 2023-03-27 | $24.34 | $24.81 | $24.09 | $24.43 | 1 046 822 |
| 2023-03-24 | $23.95 | $24.33 | $23.09 | $24.29 | 846 710 |
| 2023-03-23 | $23.97 | $24.40 | $23.50 | $23.68 | 958 688 |
About Arrowhead Research Corporation
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
